The earnings call indicates strong financial performance with significant revenue growth, improved cash flow, and positive clinical trial results, which have led to increased guidance. However, there are some concerns related to decreased cash reserves and restructuring costs. The highlights significantly outweigh the lowlights, suggesting a positive outlook.

Company Guidance -

Q3 2025

During Aurinia Pharmaceuticals' second quarter 2025 earnings call, the company provided updated guidance metrics reflecting strong performance. Total revenue for the three and six months ended June 30, 2025, was $70 million and $132.5 million, marking increases of 22% and 23% respectively, compared to the same periods in 2024. Net product sales of LUPKYNIS reached $66.6 million and $126.5 million, up 21% and 23%, respectively. The company also recorded a significant positive cash flow from operations of $45.5 million, a turnaround from the negative cash flow of $2.8 million in 2024. Aurinia raised its full-year 2025 revenue guidance to a range of $260 million to $270 million, and net product sales guidance to a range of $250 million to $260 million. Additionally, cash, cash equivalents, restricted cash, and investments totaled $315.1 million as of June 30, 2025. The company also reported a net income of $21.5 million for the quarter and announced an increase to their share repurchase plan, approving an additional $150 million in common share buybacks.

Revenue Growth

Total revenue for Q2 2025 was $70 million, up 22% from $57.2 million in Q2 2024. Net product sales of LUPKYNIS were $66.6 million, up 21% from $55 million in Q2 2024.

Increased Guidance

Full-year 2025 total revenue guidance increased from a range of $250 million to $260 million to a range of $260 million to $270 million.

Positive Cash Flow

Cash flow generated from operations was $45.5 million, compared to a negative $2.8 million in the same period of 2024.

Share Repurchase Program

Repurchased $11.2 million of common shares for $90.8 million. Board approved an increase to the share repurchase plan by up to an additional $150 million.

Positive Clinical Trial Results

Reported positive results from the aritinercept Phase I single ascending dose study, with plans to initiate further clinical studies in the second half of 2025.

Improved Gross Margin

Gross margin for Q2 2025 was 90%, compared to 84% in Q2 2024.

Aurinia Pharmaceuticals (AUPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AUPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.16 / -	0.1	―	―	―
Jul 31, 2025	2025 (Q2)	0.15 / 0.16	0.01	1500.00% (+0.15)	―
May 12, 2025	2025 (Q1)	0.10 / 0.16	-0.07	328.57% (+0.23)	―
Feb 27, 2025	2024 (Q4)	-0.02 / 0.01	-0.19	105.26% (+0.20)	―
Nov 07, 2024	2024 (Q3)	0.01 / 0.10	-0.09	211.11% (+0.19)	―
Aug 01, 2024	2024 (Q2)	<0.01 / 0.01	-0.08	112.50% (+0.09)	―
May 02, 2024	2024 (Q1)	-0.14 / -0.07	-0.18	61.11% (+0.11)	―
Feb 15, 2024	2023 (Q4)	-0.16 / -0.19	-0.18	-5.56% (-0.01)	―
Nov 02, 2023	2023 (Q3)	-0.17 / -0.09	-0.06	-50.00% (-0.03)	―
Aug 03, 2023	2023 (Q2)	-0.18 / -0.08	-0.25	68.00% (+0.17)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AUPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$9.05	$9.24	+2.10%
May 12, 2025	$8.00	$8.12	+1.50%
Feb 27, 2025	$7.95	$7.55	-5.03%
Nov 07, 2024	$7.52	$8.34	+10.90%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.